Opdivo Qvantig 120mg/2000units injection 1Vial x 5ml (nivolumab and hyaluronidase-nvhy)

Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	Opdivo Qvantig
Manufacturer	Bristol-Myers Squibb GmbH & Co.KGaA
Prescription required	Yes

Description

Opdivo Qvantig 120mg/2000units injection 1Vial x 5ml (nivolumab and hyaluronidase-nvhy) is a medicine catalog record in the MediPriceHub database. Active ingredient: nivolumab and hyaluronidase-nvhy. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Bristol-Myers Squibb GmbH & Co.KGaA. Therapeutic category: Medicine Library > Oncology Medicines > Unknown cancer drug. Pack information: 600 10000 5 ( 120 / 2000 ). Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) Melanoma Non-Small Cell Lung Cancer (NSCLC) Squamous Cell Carcinoma of the Head and Neck (SCCHN) Urothelial Carcinoma (UC) Colorectal Cancer (CRC) Hepatocellular Carcinoma (HCC) Esophageal Cancer Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib. • adult patients with advanced RCC who have received prior anti-angiogenic therapy. • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma. • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab. • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. • for the adjuvant treatment of adult and pediatric (12 years and older who weigh 30 kg or greater) patients with completel

How to Use

Use nivolumab and hyaluronidase-nvhy under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: nivolumab and hyaluronidase-nvhy. Pack size: 600 10000 5 ( 120 / 2000 ). Pack unit: bottle. Manufacturer: Bristol-Myers Squibb GmbH & Co.KGaA. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Unknown cancer drug. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Injectable and infusion products may also cause administration-site pain, swelling, infection, infusion reactions, or hypersensitivity. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.

Diese Angaben dienen nur als Referenz. Lassen Sie sich vor der Anwendung eines Medikaments von medizinischem Fachpersonal beraten.